Evaluating the Impact of Human Factors and Pen Needle Design on Insulin Pen Injection.
in vivo
injection depth
injection force variability
injection technique
intramuscular risk
pen needle
Journal
Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
19
3
2019
medline:
1
7
2020
entrez:
19
3
2019
Statut:
ppublish
Résumé
Limited published data exists quantifying the influence of human factors (HF) and pen needle (PN) design on delivery outcomes of pen injection systems. This preclinical in vivo study examines the impact of PN hub design and applied force against the skin during injection on needle penetration depth (NPD). To precisely locate injection depth, PN injections (20 µl; 2 IU, U-100 volume equivalent) of iodinated contrast agent were administered to the flank of Yorkshire swine across a range of clinically relevant application forces against the skin (0.25, 0.75, 1.25, and 2.0 lbf). The NPD, representing in vivo needle tip depth in SC tissue, from four 32 G × 4 mm PN devices (BD Nano The reengineered hub design more closely achieved the 4 mm target NPD with significantly less variability ( P = .006) than commercial posted-hub PN devices across the range of applied injection forces. Calculations of IM (intramuscular) injection risk completed through in silico probability model, using NPD and average human tissue thickness measurements, displayed a commensurate reduction (~2-8x) compared to conventional PN hub designs. Quantifiable differences in injection depth were observed between identical labeled length PN devices indicating that hub design features, coupled with aspects of variable injection technique, may influence injection depth accuracy and consistency. The reengineered hub design may reduce the impact of unintended individual technique differences by improving target injection depth consistency and reducing IM injection potential.
Sections du résumé
BACKGROUND
Limited published data exists quantifying the influence of human factors (HF) and pen needle (PN) design on delivery outcomes of pen injection systems. This preclinical in vivo study examines the impact of PN hub design and applied force against the skin during injection on needle penetration depth (NPD).
METHOD
To precisely locate injection depth, PN injections (20 µl; 2 IU, U-100 volume equivalent) of iodinated contrast agent were administered to the flank of Yorkshire swine across a range of clinically relevant application forces against the skin (0.25, 0.75, 1.25, and 2.0 lbf). The NPD, representing in vivo needle tip depth in SC tissue, from four 32 G × 4 mm PN devices (BD Nano
RESULTS
The reengineered hub design more closely achieved the 4 mm target NPD with significantly less variability ( P = .006) than commercial posted-hub PN devices across the range of applied injection forces. Calculations of IM (intramuscular) injection risk completed through in silico probability model, using NPD and average human tissue thickness measurements, displayed a commensurate reduction (~2-8x) compared to conventional PN hub designs.
CONCLUSIONS
Quantifiable differences in injection depth were observed between identical labeled length PN devices indicating that hub design features, coupled with aspects of variable injection technique, may influence injection depth accuracy and consistency. The reengineered hub design may reduce the impact of unintended individual technique differences by improving target injection depth consistency and reducing IM injection potential.
Identifiants
pubmed: 30880448
doi: 10.1177/1932296819836987
pmc: PMC6501541
doi:
Substances chimiques
Insulin
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-545Références
Diabet Med. 1990 May;7(4):335-42
pubmed: 2140087
Pediatr Diabetes. 2013 Sep;14(6):459-65
pubmed: 23517449
Medscape J Med. 2008 May 20;10(5):120
pubmed: 18596953
J Biomech. 2014 Oct 17;47(13):3344-53
pubmed: 25169657
Diabetes Care. 2008 Sep;31(9):e65
pubmed: 18753661
J Diabetes Sci Technol. 2011 May 01;5(3):632-46
pubmed: 21722578
J Diabetes Sci Technol. 2018 Mar;12(2):364-372
pubmed: 29084452
Diabetes Technol Ther. 2017 Oct;19(10):603-607
pubmed: 28704062
J Diabetes Res. 2018 Jul 4;2018:1205121
pubmed: 30116732
Diabetes Technol Ther. 2011 Apr;13(4):435-42
pubmed: 21355718
Vaccine. 2011 Oct 26;29(46):8438-42
pubmed: 21821081
Somatosens Mot Res. 2006 Mar-Jun;23(1-2):37-43
pubmed: 16846958
Drug Deliv Transl Res. 2015 Aug;5(4):332-45
pubmed: 26037035
Clin Ther. 2013 Jul;35(7):923-933.e4
pubmed: 23790553
Diabetes Care. 1990 Jan;13(1):74-6
pubmed: 2404719
J Clin Transl Endocrinol. 2014 Jul 23;1(4):145-150
pubmed: 29159095
Mayo Clin Proc. 2016 Sep;91(9):1231-55
pubmed: 27594187
Drug Metab Dispos. 2000 Feb;28(2):155-60
pubmed: 10640512
Pharm Res. 2011 Jan;28(1):107-16
pubmed: 20354765
Diabetes Technol Ther. 2011 Apr;13(4):451-6
pubmed: 21355717
J Diabetes Sci Technol. 2012 Mar 01;6(2):328-35
pubmed: 22538142
Vaccine. 2007 Aug 21;25(34):6423-30
pubmed: 17640778
Diabetes Ther. 2017 Dec;8(6):1309-1318
pubmed: 29027634
Mayo Clin Proc. 2016 Sep;91(9):1224-30
pubmed: 27594186
Ther Deliv. 2012 Mar;3(3):357-71
pubmed: 22833995
Diabetes Technol Ther. 2009 Jun;11(6):329-37
pubmed: 19459760
Diabet Med. 2005 Oct;22(10):1444-5
pubmed: 16176210
Diabetes Technol Ther. 2011 Apr;13(4):443-50
pubmed: 21355716
Eur J Pharm Sci. 2015 Nov 15;79:96-101
pubmed: 26341408
Clin Endocrinol (Oxf). 2011 Dec;75(6):786-90
pubmed: 21623860
BMJ Open Diabetes Res Care. 2016 Dec 15;4(1):e000266
pubmed: 28074137
Pediatr Diabetes. 2012 Nov;13(7):525-33
pubmed: 22583390
Eur J Pharm Biopharm. 2015 Jan;89:134-44
pubmed: 25460581
Curr Opin Mol Ther. 2010 Aug;12(4):461-70
pubmed: 20677097
Med Eng Phys. 2007 May;29(4):413-31
pubmed: 16938481
J Diabetes Sci Technol. 2012 Mar 01;6(2):389-93
pubmed: 22538152
Diabet Med. 1990 Aug;7(7):600-2
pubmed: 2146067
Med Eng Phys. 2012 Jul;34(6):665-80
pubmed: 22621782
Space Life Sci. 1972 Jun;3(3):226-34
pubmed: 4556756
Diabetes Metab J. 2014 Apr;38(2):120-33
pubmed: 24851206
J Diabetes Sci Technol. 2014 May;8(3):453-7
pubmed: 24876605
Vet Pathol. 2012 Mar;49(2):344-56
pubmed: 21441112
Diabetes Technol Ther. 2014 Dec;16(12):867-73
pubmed: 25329935
Med Devices (Auckl). 2016 May 11;9:93-103
pubmed: 27274319
Diabetes Technol Ther. 2012 Aug;14(8):741-7
pubmed: 22537418
J Diabetes Sci Technol. 2013 Jan 01;7(1):227-37
pubmed: 23439181
J Diabetes Sci Technol. 2015 Aug 27;9(6):1282-91
pubmed: 26319228
J Diabetes Sci Technol. 2009 Jul 01;3(4):986-91
pubmed: 20144350
Curr Med Res Opin. 2010 Jun;26(6):1519-30
pubmed: 20429833
Diabetes Care. 1990 May;13(5):473-7
pubmed: 2190773
J Diabetes Sci Technol. 2012 Jul 01;6(4):743-54
pubmed: 22920798